Drug Trial Radar · NCT06510452
Antibiotic Prophylaxis in Metabolic Bariatric Surgery
Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,352
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Dec 1, 2025
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, EgyptGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jul 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
SUMMARY Rationale: Prophylactic antibiotics in laparoscopic surgeries, including Metabolic Bariatric Surgery (MBS), are routinely provided to reduce postoperative infections, especially at wound incision sites. However, since incisional wound infections in laparoscopic MBS are rare and morbidity is very low, the benefit of antibiotic prophylaxis is questionable. Objective: Evaluate the non-inferiority of omitting antibiotic prophylaxis in MBS. Compare postoperative outcomes between Group A (no antibiotics) and Group B (standard antibiotic care) to determine if omission increases complications, particularly wound infections. Study Design: Randomized controlled trial (RCT), double-blind. Study Population: Patients with obesity eligible for MBS. Intervention: * Group A (No Antibiotic Prophylaxis): Undergo MBS without antibiotics to test safety regarding postoperative complications, focusing on surgical site infections (SSIs). * Group B (Standard Antibiotic Prophylaxis): Receive standard one-time antibiotics before incision. Main Study Parameters/Endpoints: Compare the incidence of incisional and organ/space SSIs within six weeks post-surgery between Group A and Group B to determine if omitting antibiotics affects infection rates.
Conditions
- Antibiotic Reaction
- Wound Infection Superficial
- Wound Infection Deep
- Bariatric Surgery Candidate
- Complication,Postoperative
Interventions
2000 mg of CefazolinDrug
receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
500 mg of Metronidazole IVDrug
receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
NACL 0.9% 100 mlDrug
receive 100 ml NACL0.9% without any antibiotics in it.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of incidence of postoperative wound infections in both treatment armsTime frame: until 6 weeks post operative
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Madina Women's Hospital
Alexandria, Egypt
WeightWorks clinics
Amersfoort, Utrecht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.